Robert W. Duggan is a seasoned business leader and entrepreneur who currently serves as the Chief Executive Officer and Executive Chairman of Summit Therapeutics Inc. With a career spanning several decades, Duggan has established himself as a visionary in the biotechnology and pharmaceutical industries. He founded and led Pharmacyclics, a biopharmaceutical company focused on developing innovative cancer therapies, which he successfully took public in 2004. Under his leadership, Pharmacyclics developed and commercialized Imbruvica, a groundbreaking treatment for various types of cancer, which significantly improved patient outcomes and generated substantial revenue for the company. In 2015, Pharmacyclics was acquired by AbbVie for $21 billion, a testament to Duggan's ability to build and grow a successful enterprise. In his current role at Summit Therapeutics Inc., Duggan is at the helm of a company dedicated to developing novel therapies for infectious diseases and cancer. Summit Therapeutics, under his leadership, is focusing on advancing its lead antibiotic candidate, ridinilazole, for the treatment of Clostridioides difficile infection, a serious and potentially life-threatening condition. Additionally, the company is exploring the potential of its oncology asset, ivonescimab, in various cancer indications. Duggan's strategic vision and leadership have been instrumental in positioning Summit Therapeutics as a key player in the biopharmaceutical industry, with a strong pipeline of promising drug candidates. Beyond his professional achievements, Robert W. Duggan is known for his commitment to philanthropy and social responsibility. He has donated significant portions of his wealth to various charitable causes, including education and healthcare initiatives. Duggan's leadership style emphasizes innovation, collaboration, and a patient-centric approach, which has earned him respect and admiration within the industry. As he continues to guide Summit Therapeutics towards its mission of developing life-saving therapies, Duggan remains a driving force in the fight against some of the world's most challenging diseases.